Join us for a dynamic and thought-provoking session with Dr. Niklas Mattsson-Carlgren of Lund University, Sweden, as he explores emerging perspectives on Alzheimer’s disease (AD) — including the concept of AD as an amyloid-driven tauopathy and what the implications for the future AD landscape.
Be part of the conversation during a live Q&A session moderated by Dr. Holly Brothers — your chance to engage directly with leaders in the field.
Date: 17 June 2025 
Time: 10:00 EST, 16:00 CEST
Reserve your spot now and stay informed on the evolving AD landscape.
This webinar has been organised and funded by Biogen.
This webinar is intended for healthcare professionals only.
Learning Objectives:
- Explore biomarker progression along the Alzheimer’s disease (AD) continuum, including biological diagnosis, Braak staging, and the correlation between pathology and clinical progression
- Evaluate the relationship between amyloid and tau pathologies, and how AD may be considered an amyloid-driven tauopathy
- Identify key evidence gaps in the understanding of amyloid-tau dynamics and future implications for biomarker development
This webinar is kindly sponsored by Biogen, in partnership with AD/PD™.
Veeva ID: Biogen-265829; Date of preparation: May 2025
Speakers
Niklas Mattsson-Carlgren, MD, PhD (Speaker)
Associate Professor of Clinical Neuroscience, Board-certified specialist in Neurology and Clinical Chemistry·Clinical Memory Research Unit, Department of Clinical Sciences Malmö, Lund University and Neurology Department, Skåne University
Dr. Niklas Mattsson-Carlgren is a renowned Swedish physician and researcher from Lund University and co-lead of the BioFINDER studies. He specializes in neurodegenerative diseases, with a primary focus on AD, and has made significant contributions to the understanding of the early stages and progression of AD, particularly regarding biomarkers, brain imaging, and design of trials for potential disease-modifying therapies. He has published extensively and collaborated internationally to advance the fight against dementia-related illnesses, while also actively involved in mentoring the next generation of clinicians and scientists.
Holly M. Brothers, PhD (Moderator)
Associate Medical Director, Global Medical Affairs, Biogen
Dr. Holly Brothers is a Medical Affairs professional with 8 years of experience in industry and nearly 20 years of experience in Alzheimer’s disease (AD). During her doctoral program at The Ohio State University and postdoc at the Sanders Brown Center on Aging ADRC, she studied the relationship between neuroinflammation, vascular pathology and AD hallmark pathologies in animal models.
To learn more about tau in Alzheimer’s disease, explore the Know Tau medical education platform from Biogen